NANOBIOTIX Stock: Significant Drop Over the Week Following Phase III Study Delay
This week, Nanobiotix's stock value experienced a significant decline at the Paris Stock Exchange, amidst the anticipated postponement of clinical results for its flagship project. The stock, which had seen exceptional momentum since the start of the year, underwent a correction contrary to the positive trend observed in major indices. Investors are questioning the impact of this new schedule in a biotechnology sector accustomed to high volatility.
Weekly Performance Analysis
Over the past week, Nanobiotix's stock closed at €16.12, marking a decrease of 32.13%. This decline comes as its twelve-month performance remains particularly high, with an annual increase of 260%. The stock, highly sought after in 2025, had reached a peak of €25.50 before experiencing this sudden correction. For comparison, the benchmark indices CAC 40 and SBF 120 remained nearly stable over the same period, increasing by 0.45% and 0.53% respectively. The discrepancy highlights the specific nature of the downturn observed in Nanobiotix, while most French stocks showed a form of stability. For the current year, the stock had so far displayed a meteoric rise, driven by expectations around its medical candidate for head and neck cancers. The volatility of the stock remains particularly pronounced, having fluctuated from €2.62 to €25.50 since the beginning of the year, a twelve-month low and a five-year high.
Reasons Behind This Week's Decline
The decline observed this week originates from the announcement on Friday of a one-year delay in the publication of the first results of the Phase III clinical trial for its flagship treatment. Nanobiotix specified that the responsibility for the study had been transferred to Johnson & Johnson and that the interim data would now only be available in the first half of 2027, whereas they were initially expected by mid-2026. This announcement surprised the market, which is accustomed to anticipating the duration of clinical trials. According to analysts publishing immediately after the announcement, this delay is linked to the complexity of recruiting patients for this type of tumor. Concerns now focus on the impact of such a rescheduling of the calendar, while the financial visibility set by the company extended until mid-2026. The shift in this timeline immediately weighed on the valuation, erasing a significant portion of the gains made since the beginning of the year.
Technical Thresholds and Market Indicators
Nanobiotix's stock is now trading between distant technical thresholds, with support identified at €7.95 and resistance at €24.45. The 50-day moving average stands at €13.23, indicating a position of the course slightly above this trend indicator. The 200-day moving average, recorded at €6.20, however, reflects a persistent link with the strong valuation observed for several months. The weekly RSI, at 43, shows no excessive tension in selling or buying. The one-month volatility is at 36.48, illustrating the magnitude of movements on the stock. The Bollinger Bands frame the action between €13.61 and €26.34. Regarding oscillators, the MACD remains on a positive trajectory with a line at 1.75. All these indicators confirm the resurgence of volatility and the highly dynamic evolution of the stock in an uncertain environment.
